================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

             Date of Report (Date of earliest reported): May 4, 2006

                                 XACT AID, INC.

               (Exact name of registrant as specified in charter)


          Delaware                     000-25022                  113718650
----------------------------          -----------            -------------------
(State or other jurisdiction          (Commission               (IRS Employer
      of incorporation)               File Number)           Identification No.)


         143 Triunfo Canyon Road, Suite 104, Westlake Village, CA 91361
       Registrant's telephone number, including area code: (805) 494-7838

                                   Copies to:
                             Darrin M. Ocasio, Esq.
                       Sichenzia Ross Friedman Ference LLP
              1065 Avenue of the Americas New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act 17 CFR 240.13e-4(c))

================================================================================

<PAGE>

Section 1 - Registrant's Business and Operations.

ITEM 1.01 - ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

SALE OF BROOKE CARLYLE LIFE SCIENCES, INC. STOCK

On May 4, 2006, the Xact Aid, Inc. (the "Company") entered into a Stock Purchase
Agreement (the "Agreement") with Nexgen Biogroup, Inc. ("Nexgen"),  for the sale
of the  1,000,000  shares (the  "Shares") of the common stock of Brooke  Carlyle
Life Sciences, Inc. ("Brooke Carlyle") held by the Company, which represents all
or substantially all of the assets of the Company, for $1,000 cash, representing
a consideration of $.001 per share of Brooke Carlyle, Brooke Carlyle's par value
per Share (the "Sale").  Also, on May 4, 2006, the Company's  Board of Directors
and  the  shareholders  of the  Company  holding  the  majority  of  issued  and
outstanding shares of the Company's common stock approved and accepted the offer
for the Sale of Brooke Carlyle stock to Nexgen,  thus authorizing the Company to
enter into the Agreement. The Board believes that the Sale of the Brooke Carlyle
stock is in the best interests of the Company and its  shareholders  in order to
satisfy and comply with the terms of the Share  Exchange  Agreement  (the "Share
Agreement") requiring the Sale of the Brooke Carlyle stock, as further explained
below. The Board of Directors further believes that such Sale in connection with
entering  into  the  Share  Agreement  will  provide  to the  Company  the  best
opportunity to proceed with  restructuring  its business via the  acquisition of
Technorient.

Brooke  Carlyle is a  development  stage  company in the business of  developing
biomedical testing products. In accordance with the terms of the Agreement,  the
Company  agreed to: (i) sell,  assign and  transfer to Nexgen any and all of its
rights,  title and  interests  in Brooke  Carlyle;  and (ii)  transfer to Nexgen
1,000,000 shares of Brooke Carlyle common stock.

SHARE EXCHANGE AGREEMENT

On March 3,  2006,  the  Company  entered  into a  non-binding  letter of intent
("LOI") with Technorient,  Limited  ("Technorient"),  a company formed under the
laws of Hong Kong, for a proposed share  exchange with  Technorient  (the "Share
Exchange").  Pursuant to the LOI, the Company  intended to acquire not less than
99.92% of the  capital  stock of  Technorient  in exchange  for the  issuance of
shares of the Company's Preferred Stock which were proposed to be authorized and
would be convertible  into 95% of the outstanding  capital stock of the Company,
as was disclosed in a definitive  Information  Statement on Schedule 14(c) filed
with the  Securities  and Exchange  Commission  ("SEC") on March 28,  2006,  and
mailed to the Company's shareholders on March 30, 2006. In early May of 2006 the
Board of Directors  was  presented  with the agreement as referred to in the LOI
for the share exchange with  Technorient.  On May 4, 2006 the Board of Directors
of the Company and shareholders holding the majority of the Company's issued and
outstanding common stock, approved for the Company to enter into said agreement.

On June 9, 2006,  the Share  Exchange  Agreement  (the  "Share  Agreement")  was
entered into by and among the  Company,  Fred De Luca, a director of the Company
("De  Luca");  Corich,  Enterprises  Ltd.  ("Corich"),  Herbert  Adamczyk  ("Mr.
Adamczyk";  Mr. Adamczyk and Corich are hereinafter  collectively referred to as
the  "Sellers");  and  Technorient  (the  Company,  De  Luca,  the  Sellers  and
Technorient are hereinafter collectively referred to as the "Parties"). Pursuant
to the terms of the Share Agreement,  the Company shall acquire from the Sellers
not less than 99.92% of the capital stock of Technorient in consideration of the
Company  issuing to the Sellers Series A Convertible  Preferred Stock which will
be  convertible  into  1,433,361,000  shares of the Company's  Common Stock (the
"Issuance"), representing 95% of the outstanding capital stock of the Company on
a fully diluted basis, taking into account the Issuance.  After giving effect to
the  Issuance,  there  will be  approximately  1,508,801,053  shares  issued and
outstanding of the Company's common stock.

Conditions  precedent to the closing of the Share Agreement include, but are not
limited  to,  (i)  that  the  holders  of the  Company's  10%  Callable  Secured
Convertible  Notes (the  "Notes") in the  aggregate  amount of  $1,000,000  will
convert the Notes into  44,060,282  shares of the Company's  common stock;  (ii)
that Edward W. Withrow,  III, a related  party of the Company,  holder a certain
note in the  principal  amount of $950,000  convert such amount into  16,600,000
restricted shares of the Company's common stock; and (iii) that the Company,  at
Closing, as defined in the Share Agreement (the "Closing"), shall have no assets
or  liabilities,  such that on or before the Closing the Company shall  transfer
all of its assets,  including the shares of Brooke Carlyle Life Sciences,  Inc.,
and  liabilities  to a third party or parties  reasonably  acceptable to Seller.
Closing of the acquisition is scheduled for July 30, 2006.

Technorient  is a Hong  Kong  based  company  whose  principal  business  is the
importation  and  distribution  of luxury  sports  cars in Hong Kong,  Macau and
China.  Through its wholly owned operating  subsidiaries Italian Motors Ltd. and
Autoitalia Ltd.,  Technorient has operated as exclusive  distributor for Ferrari
and Maserati brand motorcars in Hong Kong and Macau since 1984 and, from 1994 to
2004, in the Peoples  Republic of China ("China").  Since 2004,  Technorient has
been  developing a dealer  network in China to work closely with the Ferrari SpA
controlled distributor based in Shanghai.

On June 12, 2006, the Company  issued a press release  announcing the entry into
the  aforementioned  material  agreement.  A copy of this press release has been
filed with this Current  Report on Form 8-K as Exhibit 99.1 and is  incorporated
herein by reference.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

See Item 1.01


<PAGE>

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a)   Financial statements of business acquired.

Not applicable.

(b)   Pro forma financial information.

Not applicable.

(c)   Pro forma financial information.

Not applicable.

(d)   Exhibits.

    Exhibit
    Number        Description
    --------      --------------------------------------------------------------
    10.1          Share Exchange  Agreement,  by and among the Company;  Fred De
                  Luca,   Corich   Enterprises,   Inc.,   Herbert  Adamczyk  and
                  Technorient, Limited, dated June 9, 2006. (Filed herewith).

    10.2          Stock Purchase Agreement,  entered into on May 4, 2006, by and
                  between  the  Company  and  Nexgen   Biogroup,   Inc.   (Filed
                  herewith).

    99.1          Press Release issued by Xact Aid,  Inc.,  dated June 12, 2006.
                  (Filed herewith).

    99.2          Press Release issued by Xact Aid,  Inc.,  dated June 13, 2006.
                  (Filed herewith).


<PAGE>

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        XACT AID, INC.


Date: June 14, 2006                     /s/ Robert G. Pautsch
                                        -----------------------------------
                                            Robert G. Pautsch
                                            President
{"company-data": {"conformed-name": "XACT AID INC", "cik": "0001309346", "assigned-sic": "2834", "irs-number": "113718650", "state-of-incorporation": "NV", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-120807", "film-number": "06905680"}, "business-address": {"street1": "5655 LINDERO CANYON ROAD", "street2": "SUITE 106", "city": "WESTLAKE VILLAGE", "state": "CA", "zip": "91362", "phone": "866-922-8243"}, "mail-address": {"street1": "5655 LINDERO CANYON ROAD", "street2": "SUITE 106", "city": "WESTLAKE VILLAGE", "state": "CA", "zip": "91362"}}
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

             Date of Report (Date of earliest reported): May 4, 2006

                                 XACT AID, INC.

               (Exact name of registrant as specified in charter)

          Delaware                     000-25022                  113718650
----------------------------          -----------            -------------------
(State or other jurisdiction          (Commission               (IRS Employer
      of incorporation)               File Number)           Identification No.)

         143 Triunfo Canyon Road, Suite 104, Westlake Village, CA 91361
       Registrant's telephone number, including area code: (805) 494-7838

                                   Copies to:
                             Darrin M. Ocasio, Esq.
                       Sichenzia Ross Friedman Ference LLP
              1065 Avenue of the Americas New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act 17 CFR 240.13e-4(c))

================================================================================
Section 1 - Registrant's Business and Operations.

ITEM 1.01 - ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

SALE OF BROOKE CARLYLE LIFE SCIENCES, INC. STOCK

On May 4, 2006, the Xact Aid, Inc. (the "Company") entered into a Stock Purchase
Agreement (the "Agreement") with Nexgen Biogroup, Inc. ("Nexgen"),  for the sale
of the  1,000,000  shares (the  "Shares") of the common stock of Brooke  Carlyle
Life Sciences, Inc. ("Brooke Carlyle") held by the Company, which represents all
or substantially all of the assets of the Company, for $1,000 cash, representing
a consideration of $.001 per share of Brooke Carlyle, Brooke Carlyle's par value
per Share (the "Sale").  Also, on May 4, 2006, the Company's  Board of Directors
and  the  shareholders  of the  Company  holding  the  majority  of  issued  and
outstanding shares of the Company's common stock approved and accepted the offer
for the Sale of Brooke Carlyle stock to Nexgen,  thus authorizing the Company to
enter into the Agreement. The Board believes that the Sale of the Brooke Carlyle
stock is in the best interests of the Company and its  shareholders  in order to
satisfy and comply with the terms of the Share  Exchange  Agreement  (the "Share
Agreement") requiring the Sale of the Brooke Carlyle stock, as further explained
below. The Board of Directors further believes that such Sale in connection with
entering  into  the  Share  Agreement  will  provide  to the  Company  the  best
opportunity to proceed with  restructuring  its business via the  acquisition of
Technorient.

Brooke  Carlyle is a  development  stage  company in the business of  developing
biomedical testing products. In accordance with the terms of the Agreement,  the
Company  agreed to: (i) sell,  assign and  transfer to Nexgen any and all of its
rights,  title and  interests  in Brooke  Carlyle;  and (ii)  transfer to Nexgen
1,000,000 shares of Brooke Carlyle common stock.

SHARE EXCHANGE AGREEMENT

On March 3,  2006,  the  Company  entered  into a  non-binding  letter of intent
("LOI") with Technorient,  Limited  ("Technorient"),  a company formed under the
laws of Hong Kong, for a proposed share  exchange with  Technorient  (the "Share
Exchange").  Pursuant to the LOI, the Company  intended to acquire not less than
99.92% of the  capital  stock of  Technorient  in exchange  for the  issuance of
shares of the Company's Preferred Stock which were proposed to be authorized and
would be convertible  into 95% of the outstanding  capital stock of the Company,
as was disclosed in a definitive  Information  Statement on Schedule 14(c) filed
with the  Securities  and Exchange  Commission  ("SEC") on March 28,  2006,  and
mailed to the Company's shareholders on March 30, 2006. In early May of 2006 the
Board of Directors  was  presented  with the agreement as referred to in the LOI
for the share exchange with  Technorient.  On May 4, 2006 the Board of Directors
of the Company and shareholders holding the majority of the Company's issued and
outstanding common stock, approved for the Company to enter into said agreement.

On June 9, 2006,  the Share  Exchange  Agreement  (the  "Share  Agreement")  was
entered into by and among the  Company,  Fred De Luca, a director of the Company
("De  Luca");  Corich,  Enterprises  Ltd.  ("Corich"),  Herbert  Adamczyk  ("Mr.
Adamczyk";  Mr. Adamczyk and Corich are hereinafter  collectively referred to as
the  "Sellers");  and  Technorient  (the  Company,  De  Luca,  the  Sellers  and
Technorient are hereinafter collectively referred to as the "Parties"). Pursuant
to the terms of the Share Agreement,  the Company shall acquire from the Sellers
not less than 99.92% of the capital stock of Technorient in consideration of the
Company  issuing to the Sellers Series A Convertible  Preferred Stock which will
be  convertible  into  1,433,361,000  shares of the Company's  Common Stock (the
"Issuance"), representing 95% of the outstanding capital stock of the Company on
a fully diluted basis, taking into account the Issuance.  After giving effect to
the  Issuance,  there  will be  approximately  1,508,801,053  shares  issued and
outstanding of the Company's common stock.

Conditions  precedent to the closing of the Share Agreement include, but are not
limited  to,  (i)  that  the  holders  of the  Company's  10%  Callable  Secured
Convertible  Notes (the  "Notes") in the  aggregate  amount of  $1,000,000  will
convert the Notes into  44,060,282  shares of the Company's  common stock;  (ii)
that Edward W. Withrow,  III, a related  party of the Company,  holder a certain
note in the  principal  amount of $950,000  convert such amount into  16,600,000
restricted shares of the Company's common stock; and (iii) that the Company,  at
Closing, as defined in the Share Agreement (the "Closing"), shall have no assets
or  liabilities,  such that on or before the Closing the Company shall  transfer
all of its assets,  including the shares of Brooke Carlyle Life Sciences,  Inc.,
and  liabilities  to a third party or parties  reasonably  acceptable to Seller.
Closing of the acquisition is scheduled for July 30, 2006.

Technorient  is a Hong  Kong  based  company  whose  principal  business  is the
importation  and  distribution  of luxury  sports  cars in Hong Kong,  Macau and
China.  Through its wholly owned operating  subsidiaries Italian Motors Ltd. and
Autoitalia Ltd.,  Technorient has operated as exclusive  distributor for Ferrari
and Maserati brand motorcars in Hong Kong and Macau since 1984 and, from 1994 to
2004, in the Peoples  Republic of China ("China").  Since 2004,  Technorient has
been  developing a dealer  network in China to work closely with the Ferrari SpA
controlled distributor based in Shanghai.

On June 12, 2006, the Company  issued a press release  announcing the entry into
the  aforementioned  material  agreement.  A copy of this press release has been
filed with this Current  Report on Form 8-K as Exhibit 99.1 and is  incorporated
herein by reference.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

See Item 1.01
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a)   Financial statements of business acquired.

Not applicable.

(b)   Pro forma financial information.

Not applicable.

(c)   Pro forma financial information.

Not applicable.

(d)   Exhibits.

    Exhibit
    Number        Description
    --------      --------------------------------------------------------------
    10.1          Share Exchange  Agreement,  by and among the Company;  Fred De
                  Luca,   Corich   Enterprises,   Inc.,   Herbert  Adamczyk  and
                  Technorient, Limited, dated June 9, 2006. (Filed herewith).

    10.2          Stock Purchase Agreement,  entered into on May 4, 2006, by and
                  between  the  Company  and  Nexgen   Biogroup,   Inc.   (Filed
                  herewith).

    99.1          Press Release issued by Xact Aid,  Inc.,  dated June 12, 2006.
                  (Filed herewith).

    99.2          Press Release issued by Xact Aid,  Inc.,  dated June 13, 2006.
                  (Filed herewith).
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        XACT AID, INC.

Date: June 14, 2006                     /s/ Robert G. Pautsch
                                        -----------------------------------
                                            Robert G. Pautsch
                                            President